Combination therapy for malignant diseases
A new approach for the treatment of a malignant disease is provided. The new method comprises administering a traditional anti-cancer therapy in combination with a DNA or protein vaccine comprising CTLA-4 and PD-1, or a DNA or protein vaccine comprising CTLA-4 and PD-L1.
1. A method for treating a malignant disease in a subject, comprising administering to said subject a vaccine in combination with a radiation treatment, in which the vaccine is a pharmaceutical composition comprising a DNA construct comprising a polynucleotide sequence encoding Cytotoxic T-lymphocyte antigen-4 (CTLA-4) and a PD-1 or a programmed cell death 1 ligand 1 (PD-L1), or combination thereof, wherein the malignant disease is colorectal cancer.
2. The method of claim 1 , wherein the vaccine is a DNA vaccine comprising a polynucleotide sequence encoding CTLA-4 and PD-L1 or a DNA vaccine comprising a polynucleotide sequence encoding CTLA-4-PD-L1.
3. The method of claim 1 , wherein the vaccine is a DNA vaccine comprising CTLA-4 and PD-1 or a DNA vaccine comprising CTLA-4-PD-1.
4. A method for treating a malignant disease in a subject, comprising administering to said subject a vaccine in combination with a radiation treatment, in which the vaccine is a pharmaceutical composition comprising a DNA construct comprising a polynucleotide sequence encoding Cytotoxic T-lymphocyte antigen-4 (CTLA-4), and a DNA construct comprising a polynucleotide sequence encoding PD-1 or a programmed cell death 1 ligand 1 (PD-L1), or combination thereof, wherein the malignant disease is colorectal cancer.
5. A method for treating a malignant disease in a subject, comprising administering to said subject a radiotherapy in association with a combination of a DNA construct comprising a polynucleotide sequence encoding CTLA-4, and a DNA construct comprising a polynucleotide sequence encoding PD-1 or PD-L1, wherein the malignant disease is colorectal cancer.
6. The method of claim 5 , comprising administering to said subject a radiotherapy in combination of a DNA vaccine comprising a polynucleotide sequence encoding CTLA-4 and PD-1, or a DNA vaccine comprising a polynucleotide sequence encoding CTLA-4-PD-1.